Tirabrutinib (Velexbru)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 02:00, 11 June 2023 by Warner-admin (talk | contribs) (Text replacement - ": new" to ": New")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Mechanism of action

BTK inhibitor

Diseases for which it is used

History of changes in PMDA indication

2020-03-25: Newly indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma.
2020-08-21: New indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.

Also known as

Code name: GS-4059
Brand name: Velexbru

Retrieved from "https://hemonc.org/w/index.php?title=Tirabrutinib_(Velexbru)&oldid=73192"